Capsida Biotherapeutics, Inc.
Clinical trials sponsored by Capsida Biotherapeutics, Inc., explained in plain language.
-
One-Shot gene therapy trial aims to help kids with rare brain disease
Disease control TerminatedThis early-stage trial is testing a single dose of an experimental gene therapy called CAP-002 in children aged 18 months to 8 years with a rare genetic brain condition called STXBP1 encephalopathy. The main goal is to check if the treatment is safe and tolerable, while also look…
Phase: PHASE1, PHASE2 • Sponsor: Capsida Biotherapeutics, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
One-Shot gene therapy tested to halt Parkinson's progression
Disease control TerminatedThis early-stage trial is testing a new, one-time gene therapy called CAP-003 in adults with Parkinson's disease caused by a specific genetic change (GBA1 mutation). The main goals are to see if the treatment is safe and to look for early signs that it might help control the dise…
Phase: PHASE1, PHASE2 • Sponsor: Capsida Biotherapeutics, Inc. • Aim: Disease control
Last updated Mar 02, 2026 15:28 UTC